Header

Why Glyxambi®?

img

Powerful Efficacy.
Ensured Safety.
Convenient Dosing.

Efficacy

Powerful glycaemic control with Empagliflozin+Linagliptin1

Powerful glycaemic control with Empa and Lina

* Patients uncontrolled on metformin with a mean baseline HbA1c of ≥8.5%. Subgroup analysis (exploratory endpoint).

FDC: Fixed-dose combination. HbAlc: Glycated haemoglobin. EMPA: Empagliflozin. LINA: Linagliptin.

Reference:

  1. DeFronzo RA, et al. Diabetes Care. 2015;38(3):384-393.(Based on subgroup analysis of patients with HbA1c ≥8.5% at baseline).

Early goal achievement with Empagliflozin+Linagliptin even at 8% baseline HbA1c¹

Early goal

FDC: Fixed-dose combination. MET: Metformin. HbA1e: Glycated haemoglobin. EMPA: Empagliflozin. LINA: Linagliptin. SE: Standard error.

References:

  1. Lewin A, et al. Diabetes Care. 2015;38(3):394-402.

  2. DeFronzo RA, et al. Diabetes Care. 2015;38(3):384-393. (Based on subgroup analysis of patients with HbA1c 2::8.5o/o at baseline).